Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab Master Continuation Study (B9991046)
2023-509466-38-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 18
01
Overview
Phase 3, open-label, single-arm trial of avelumab in cancer, sponsored by Pfizer. Primary endpoints: Adverse events leading to permanent discontinuation of study intervention and Serious adverse events. Planned start Aug 2024; status: authorised.
02
Drugs
avelumab
03
Conditions
cancer
Beyond the preview
Go deeper on 2023-509466-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509466-38-00.